Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Qinsong Oral Liquid is an investigational botanical or herbal therapeutic developed by Suzhou Siyuan Natural Products Research and Development Co., Ltd. for the treatment of acute pharyngitis. It is formulated as an oral liquid and has been evaluated in Phase 1 clinical trials in China (e.g., CTR20170846) to assess the safety, tolerance, and pharmacokinetics of single oral doses in healthy volunteers. As a natural product-derived medication, its therapeutic effect is likely mediated through a combination of anti-inflammatory and antimicrobial activities typical of traditional Chinese medicine treatments for upper respiratory tract inflammations.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Qinsong Oral Liquid.